Clinical Trial Update: Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of gemcitabine, cisplatin, and nivolumab in muscle-invasive bladder cancer with selective bladder-sparing has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: Matthew Galsky | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-06-27